HDFC Pharma and Healthcare Fund
Holdings
39
Concentrated
Top 10 weight
52%
Concentration
Active share
91%
Highly Differentiated
Equity
100%
Asset allocation
Portfolio
3Sectors
2Large positions
71.2%Top: Pharmaceuticals & Biotechnology
0.0%Cash
Market-cap allocation
Large cap34%
Mid cap28%
Small cap35%
Asset allocation
Equity100%
Top holdings
9.7%
Divis Laboratories Ltd.EQUITY
9.1%4.8%
4.7%
Lupin Ltd.EQUITY
4.7%Cipla Ltd.EQUITY
4.6%Alkem Laboratories Ltd.EQUITY
3.7%3.6%
3.6%
3.4%
Ipca Laboratories Ltd.EQUITY
3.2%TREPS - Tri-party RepoDERIVATIVE
3.1%Global Health LimitedEQUITY
3.1%2.8%
2.6%
2.5%
2.3%
Shilpa Medicare LtdEQUITY
2.3%2.2%
2.1%
2.1%
Biocon Ltd.EQUITY
2.0%1.9%
Wockhardt Ltd.EQUITY
1.9%1.6%
Rubicon Research LimitedEQUITY
1.6%1.6%
1.4%
Ajanta Pharma LimitedEQUITY
1.3%Eris Lifesciences LtdEQUITY
1.3%CORONA REMEDIES LIMITEDEQUITY
1.2%Gland Pharma Ltd.EQUITY
1.1%1.0%
BAJAJ HEALTHCARE LIMITEDEQUITY
0.65%Novartis India Ltd.EQUITY
0.51%Laxmi Dental LimitedEQUITY
0.47%0.36%
Net Current AssetsDERIVATIVE
-2.6%AI Smart summary
Portfolio read
- 100% equity.
- 39 disclosed positions across 3 classified equity sectors.
- Largest equity sector is Pharmaceuticals & Biotechnology at 71.2% of the portfolio.
Watchpoints
- Small-cap exposure is 35%, which may increase volatility and liquidity risk.
- Sector concentration is elevated: Pharmaceuticals & Biotechnology represents 71%.
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in Sectoral / Thematic.
HDFC Manufacturing fund91 holdings · 34% top 10 · 80% AS
UTI Quant Fund89 holdings · 36% top 10
Icici Prudential Energy Opportunities Fund88 holdings · 43% top 10 · 83% AS
ICICI Prudential Business Cycle Fund86 holdings · 50% top 10 · 70% AS
Edelweiss Technology Fund84 holdings · 54% top 10
Axis Business Cycles Fund81 holdings · 29% top 10 · 67% AS
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
71.2%
27.9%
0.5%